Drugs / charcoal
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT03802487 Background | Jan → Mar 2019 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03060044 Comparator | Jul → Nov 2016 | asthma | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02162485 Comparator | Jun 2014 → Sep 2015 | asthma | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01856621 Comparator | May → Sep 2013 | asthma | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01766843 Comparator | Jan → May 2013 | asthma | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01627158 Background | Jun → Oct 2012 | asthma | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01863888 Background | Oct 2013 → Jan 2015 | multiple sclerosis | Sanofi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Charcoal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03802487 ↗ |
| Known as | Carbomix granules | “concomitant charcoal administration (Carbomix granules)” NCT02162485 ↗ |
| Route | Oral | “Route of administration: oral” NCT01863888 ↗ |